CAJ | 학술논문

目的观察雷珠单抗联合光动力治疗息肉样脉络膜视网膜病变(PCV)临床治疗效果.方法经眼底检查及ICGA造影检查确诊PCV患者1 7例,17只眼,所有病人于光动力治疗前2天给予玻璃体腔注射雷珠单抗0.5 rmg/0.05 mL,再行常规光动力治疗,观察治疗后1年患者视力,黄斑视网膜厚度变化,眼底息肉样病变消退,黄斑病变区出血吸收及相关眼部和全身并发症情况.结果所有患者均完成1年期随访,观察期结束时29.5％患者视力较治疗前提高,58.7％视力无变化,11.8％视力下降,治疗后所有患者LogMAR视力结果较治疗前提高,治疗前视力(0.56±0.31) Log-MAR,治疗后视力(0.37±0.19) LogMAR,差异有统计学意义(P＜0.05),黄斑视网膜厚度从治疗前(427.3±143.6) μm到治疗后(255.2±115.9) μm,差异有统计学意义(P＜0.01),观察期间2例患者PCV复发,再次行光动力治疗,所有患者未见玻璃体出血、眼内炎等并发症.结论雷珠单抗联合光动力治疗PCV可较快促进黄斑网膜下液吸收,提高患者视力,减少术后并发症,进一步需大样本,对照研究.
목적 관찰뢰주단항연합광동력치료식육양맥락막시망막병변(PCV)림상치료효과.방법 경안저검사급ICGA조영검사학진PCV환자1 7례,17지안,소유병인우광동력치료전2천급여파리체강주사뢰주단항0.5 rmg/0.05 mL,재행상규광동력치료,관찰치료후1년환자시력,황반시망막후도변화,안저식육양병변소퇴,황반병변구출혈흡수급상관안부화전신병발증정황.결과 소유환자균완성1년기수방,관찰기결속시29.5％환자시력교치료전제고,58.7％시력무변화,11.8％시력하강,치료후소유환자LogMAR시력결과교치료전제고,치료전시력(0.56±0.31) Log-MAR,치료후시력(0.37±0.19) LogMAR,차이유통계학의의(P＜0.05),황반시망막후도종치료전(427.3±143.6) μm도치료후(255.2±115.9) μm,차이유통계학의의(P＜0.01),관찰기간2례환자PCV복발,재차행광동력치료,소유환자미견파리체출혈、안내염등병발증.결론 뢰주단항연합광동력치료PCV가교쾌촉진황반망막하액흡수,제고환자시력,감소술후병발증,진일보수대양본,대조연구.
Objective To clarify the efficacy of combined therapy with intravitreal ranibizumab injections and photodynamic therapy in patients with symptomatic polypoidal choroidal vasculopathy.Methods Retrospectively reviewed 17 naive eyes of 17 patients treated with intravitreal injections of ranibizumab (0.5 mg/0.05 mL) combined photodynamic therapy and followed-up for at least 12 months.Photodynamic therapy was administered 1 day or 2 days after the initial injection of ranibizumab.Results The mean best-corrected visual acuity levels significantly improved from 0.56± 0.31at baseline to 0.37±0.19 at 12 months (P ＜0.05).The central retinal thickness significantly decreased from 427.3±143.6um to 255.2±115.9um at 12 months (P ＜0.001).No complications developed.Conclusions Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy can maintain or improve visual acuity and reduce the exudation.